Ethics of clinical trials: the ‘forbidden fruit’ phenomena (original) (raw)
Related papers
Moral Justification of Phase 1 Oncology Trials
This article attempts to answer the following normative questions: Can one consider the design of Phase 1 trials ethically appropriate due to the unfavorable ratio of risks and benefits? What are some ethical safeguards for Phase 1 oncology research? A comparative review of literature contributed to the consolidation of the proposed ethical framework for Phase 1 oncology trials. This framework gives a special attention to issues of therapeutic misconception and vulnerability. The benefits and dangers associated with the enrollment in trials are described as well as the absence of alternatives, treatment-specific optimism, and vagueness in factual presentation during the informed consent process. The notion of therapeutic misconception is contrasted with optimism despite realism that stems from psychological, cultural, and religious factors and not necessarily from the lack of information. Close attention is given to the possible ways in which the inherent uncertainty and resulting cognitive biases may affect the informed consent process and the definition of therapeutic misconception. The article ends with recommendations for an ethical way of enrolling palliative patients in early stages of oncology research , giving special attention to provision of adequate consent, protection of vulnerability, and avoidance of therapeutic misconception.
Media Reporting of Affordable Cancer Care in High Income Countries: a Lancet Oncology Commission
Money and cancer care were always going to be a volatile combination for this Commission (Lancet Oncology 2011 12(10): 923-980). Add in a complex subject, a lack of an educated (on the whole) media as well as strong ideological leanings and critical fusion was soon reached! One of the first phenomena to emerge was the Chinese whisper. In these days of e-media misinformation is rapidly passed on. In this case it started with the Daily Telegraph trumpeting that the conclusions were that we should deny dying patients beneficial treatments. Their strap-line 'Dying cancer patients should not be given 'futile' drugs' was pure fiction, although a lot of the text accompanying it was correct (a sizeable amount though was not). This theme rapidly caught on infecting about 40% of the subsequent e-media. To make matters worse a Daily Telegraph bloggist then repeated and even expanded on the more outlandish and frankly false 'facts'. Remarkably the viral dissemination didn't stop at e-media but managed to jump the 'species' barrier to get into radio. And not just any old radio but the BBC. From main to regional programs the 'story' was the same; doctors want to deny dying cancer patients beneficial treatment. What also emerged, however, from the radio interviews were two other serious issues. The first was an almost complete over-focus on medicines, to the point that many discussants honestly believed that cancer medicines were the key technology in the control and cure of cancer. This wasn't a complete surprise. Some time ago we conducted a study of BBC website reporting of cancer; drug stories were the dominant feature by far (Brit J Cancer 2008, 99: 569-76). What was a surprise was the inability of people to accept that this 'reality' was not true. More broadly there was an almost zero level of understanding of any of the drivers and issues to delivering affordable cancer care. The second issue was more ideological. This came through on both the responses to e-media and the radio interviews. No value can be put on a human life. To put it another way a substantial number (around 40% by my reckoning) said that we should pay for treatment or interventions no matter what the cost nor how little benefit the interventions could potentially give. The reality that nearly everything we do in life is framed within the economics of value of a statistical life was utterly rejected. Moreover the ability to see a societal duty, that these decisions had consequences and impact on other lives was given no importance. Social justice was about 'me'. Returning for a moment to the 'why' behind the almost exclusive focus on cancer medicines it is clear that the professional-industrial-media complex must take full responsibility. Fed on a daily diet of drugs, if you'll excuse the pun, is it any wonder about the huge misperceptions within the general public. Healthcare professionals and research funding organisations haven't done (Cont.
Cancer medicines: a private vice for public benefit
eCancer, 2024
Cancer medicines have become one of the most dominant global medical technologies. They generate huge profits for the biopharmaceutical industry as well as fuel the research and advocacy activities of public funders, patient organisations, clinical and scientific communities and entire federal political ecosystems. The mismatch between the price, affordability and value of many cancer medicines and global need has generated significant policy debate, yet we see little change in behaviours from any of the major actors from public research funders through to regulatory authorities. In this policy analysis we examine whether, considering the money and power inherent in this system, any rationale global consensus and policy can be achieved to deliver affordable and equitable cancer medicines that consistently deliver clinically meaningful benefit.